Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Clinical Assessment Study in Adolescents and Adults With Erythropoietic Protoporphyria (EPP) and X-Linked Porphyria (XLP) (STEPP)

NCT07567131 is registered in ClinicalTrials.gov with Portal Therapeutics, Inc. as lead sponsor.

NCT NCT07567131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07567131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Clinical Assessment Study in Adolescents and Adults With Erythropoietic Protoporphyria (EPP) and X-Linked Porphyria (XLP) (STEPP)
Lead sponsor
Portal Therapeutics, Inc.
Phase
Observational
Overall status
Recruiting
Start date
April 30, 2026
Completion date
April 1, 2027
Enrollment
50 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

erythropoietic protoporphyria (epp), x-linked porphyria (xlp)